Author: Vita Louisa Sophie Dingerkus (Switzerland)
Co-authors: Gábor Márk Somfai, Stephan Kinzl, Florian Moritz Heussen, Matthias Dieter Becker
Purpose
Reduced procedure time and increase patient safety due to a lower reported incidence of endophthalmitis are the main advantages of intravitreal injections (IVI) with prefilled syringes (PFS). In our clinic we observed an unusual incidence of severe spikes in intraocular pressure (IOP) after the introduction of the aflibercept PFS, leading to short-term transient visual loss in some of the treated eyes. Therefore, our aim was to assess the IOP changes after IVI procedures and to find out their possible cause.
Setting/Venue
Prospective case-control study at the Retina Outpatient Clinic of the Department of Ophthalmology, Waid and Triemli Hospital, Zurich, Switzerland.
Methods
IOP was measured pre- and postoperatively using a non-contact tonometer in patients receiving IVI either with ranibizumab PFS or aflibercept, either with PFS or vials (groups RP, AP and AV, respectively). A random intercept model was run with type of intravitreal injection (IVI) and pre-treatment IOP as fixed factors. A second model was also run including other possibly confounding factors (age, sex, pathology, pseudophakia, hyperopia, myopia, and number of injections). An analysis was performed with a binary outcome, i.e., IOP >30 post-treatment. A chi-square test and a mixed effects logistic regression were run to test the effect of type of IVI on IOP >30.
Results
We included 173 eyes of 141 consecutive patients in our study undergoing IVI either with AP, AV or RP at our retina outpatient clinic. Mean IOP increase was 14.23, 12.59, and 11.89mmHg for the AP, AV, and RP groups, respectively, the differences being not statistically significant. The only significant confounding factor identified as a potential risk factor for IOP rise was the pre-treatment IOP (p<0.001), with RVO in the history reaching missed significance (p=0.058). An IOP rise of >30 mmHg was observed in 40.7% in the AP group versus 31.4% in the AV, and 22.2% in the RP group, respectively, with the mixed effects logistic regression showing no statistical significance (p=0.140, AP vs. RP p=0.060). A ROC curve and Youden index showed a cutoff of 13.5, 11.5 and 11.5mmHg in the AP, AV and RP groups, respectively. All IOP rises normalized by the application of conservative therapy.
Conlusions
An increased, although not significantly higher incidence of IOP elevations above 30mmHg following IVI with the aflibercept PFS was observed in our study, warranting further research into its cause with a larger number of subjects. One possible reason may be the error-proneness of administering the correct volume with the AP that has a higher diameter compared to the other syringes used for the AV or RP injections. We could not identify any other confounding factors leading to IOP elevations following intravitreal injections.
Financial Disclosure
Gábor Márk Somfai (Consultant to Allergan, Bayer, Novartis) Stephan Kinzl (Consultant to Novartis) Matthias Becker (Consultant to Roche) All other authors declare that they have no competing interests.
Comments
-